The impact of human recombinant erythropoietin on renal function in patients with chronic Kidney disease

Nephro-Urology Monthly

Volumn 3, Issue 2, 2011, Pages 114-117

  Tamadon, Mohamad Reza ^a   Khatibinezhad, Ahmad ^a   Ghorbani, Raheb ^a   Soleimani, Alireza ^b   Malek, Farhad ^a   Jalalzadeh, Mojgan ^c   Malek, Mojtaba ^d  

^a SEMNAN UNIVERSITY   (Iran)

^b Department of Pediatrics   (Iran)

^c ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chronic kidney failure; Creatinine; Erythropoietin

Indexed keywords

CREATININE; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERVENTION STUDY; KIDNEY FUNCTION; MALE;

EID: 79953271324     PISSN: 22517006     EISSN: 22517014     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Stenvinkel P, Barany P, Heimbürger O, Pecoits-Filho R, Lindholm B. Mortality, malnutrition, and atherosclerosis in ESRD: What is the role of interleukin-6? Kidney International. 2002;61:S103-S8.
2. Pecoits-Filho R, Lindholm B, Axelsson J, Stenvinkel P. Update on interleukin-6 and its role in chronic renal failure. Nephrol Dial Transplant. 2003;18(6):1042-5.
3. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000;35(3):469-76.
4. Panichi V, Paoletti S, Mantuano E, Manca-Rizza G, Filippi C, Santi S, et al. In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients. Nephrol Dial Transplant. 2006;21(2):337-44.
5. Dornbrook-Lavender KA, Joy MS, Denu-Ciocca CJ, Chin H, Hogan SL, Pieper JA. Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis. Pharmacotherapy. 2005;25(3):335-44.
6. Mahley RW, Weisgraber KH, Bersot TP. Williams textbook of endocrinology. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, editors. 11th ed. Philadelphia: Saunders/Elsevier; 2008. p. 1633, 9.
7. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol. 2004;57(7):728-34.
8. Ikejiri A, Hirano T, Murayama S, Yoshino G, Gushiken N, Hyodo T, et al. Effects of atorvastatin on triglyceride-rich lipoproteins, lowdensity lipoprotein subclass, and C-reactive protein in hemodialysis patients. Metabolism. 2004;53(9):1113-7.
9. van den Akker JM, Bredie SJ, Diepenveen SH, van Tits LJ, Stalenhoef AF, van Leusen R. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL. J Nephrol. 2003;16(2):238-44.
10. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis. 1998;32(1):107-14.
11. Stenvinkel P, Heimburger O, Jogestrand T. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: association with Chlamydia pneumoniae seropositivity. Am J Kidney Dis. 2002;39(2):274-82.
12. Goicoechea M, de Vinuesa SG, Lahera V, Cachofeiro V, Gomez-Campdera F, Vega A, et al. Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease. J Am Soc Nephrol. 2006;17(12 Suppl 3):S231-5.